Daniel Norman, MD
Sleep Medicine · Los Angeles, CANPI 1730198730
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Harmony Biosciences LLC at 42.3% of the total. Reporting peaked in 2020 at $9,787 and has fallen 78.9% since, to $2,063 in 2025. Among sleep medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $77.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$10K
- Jazz Pharmaceuticals Inc.$7K
- Pear Therapeutics (US), Inc.$3K
- Inspire Medical Systems, Inc.$2K
- Avadel CNS Pharmaceuticals, LLC$649
- Axsome Therapeutics, Inc.$334
- plus $2K from 16 others
Across 506 payments — averaging $8282.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vanda Pharmaceuticals Inc.$3.5M
- Harmony Biosciences LLC$223K
- Jazz Pharmaceuticals Inc.$208K
- Alkermes, Inc.$155K
- Avadel CNS Pharmaceuticals, LLC$51K
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- plus $8K from 3 others
What the payments were for
- Consulting fees$9,15439%
- Speaking & faculty fees$5,40023%
- Travel & lodging$8674%
- Food & beverage$7,91733%
- Education$3501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harmony Biosciences LLC | 96 | $10,027 |
| Jazz Pharmaceuticals Inc. | 93 | $6,536 |
| Pear Therapeutics (US), Inc. | 1 | $3,079 |
| Inspire Medical Systems, Inc. | 12 | $1,555 |
| Avadel CNS Pharmaceuticals, LLC | 21 | $649 |
| Axsome Therapeutics, Inc. | 15 | $334 |
| Akorn Operating Company LLC | 12 | $193 |
| Arbor Pharmaceuticals, Inc. | 9 | $181 |
| Idorsia Pharmaceuticals US Inc | 9 | $171 |
| Eisai Inc. | 8 | $159 |
| Lilly USA, LLC | 6 | $133 |
| Merck | 7 | $118 |
| Noctrix Health, Inc. | 1 | $108 |
| Resmed Corp | 1 | $92 |
| Itamar Medical Inc | 1 | $85 |
| Azurity Pharmaceuticals, Inc. | 5 | $81 |
| AstraZeneca | 2 | $41 |
| Optinose US, Inc. | 2 | $40 |
| Boehringer Ingelheim | 2 | $40 |
| Grifols USA, LLC | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| GSK | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,688 in reported general payments places this provider in the 90th percentile of 200 sleep medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XyremSodium Oxybate | 14 | $301,218 |
| LumryzSodium Oxybate | 12 | $139,447 |
| DayvigoLemborexant | 54 | $21,357 |
| BelsomraSuvorexant | 37 | $16,720 |
| QuviviqDaridorexant Hcl | 24 | $11,230 |
| Mirtazapine | 63 | $2,236 |
| Zolpidem Tartrate | 38 | $1,503 |
| Azelastine Hcl | 40 | $1,409 |
| Modafinil | 33 | $1,231 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 24 | $1,005 |
| Ramelteon | 18 | $879 |
| Acetazolamide | 21 | $689 |
| Armodafinil | 18 | $382 |
| Fluticasone Propionate | 23 | $377 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $346 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Avadel CNS Pharmaceuticals, LLCLumryz | $649 | $139,44712 claims |
| Eisai Inc.Dayvigo | $159 | $21,35754 claims |
| MerckBelsomra | $118 | $16,72037 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $171 | $11,23024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 200 sleep medicine providers in California.
Other sleep medicine in Los Angeles
- Arun RamachandranLos Angeles$17K
- Payam ShadiLos Angeles$10K
- Lisa ShivesSan Diego$1.4M
- Haramandeep SinghSan Ramon$1.1M
- Atul MalhotraSan Diego$771K
- Logan SchneiderStanford$506K
- Tony MasriLos Gatos$327K
- Sam KashaniSanta Monica$221K
- Emmanuel MignotStanford$135K
- Jerome HesterPalo Alto$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.